A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan

Introduction: In Japan, the PMDA conducted inspections based on GCP in the review process of the submission of NDAs or sNDAs. In this descriptive study, we examined in detail the contents of exclusion data from submitted clinical data package subjects in the results of GCP inspections in Japan for N...

Full description

Bibliographic Details
Main Authors: Ryuta Asada, Kenichi Yoshimura, Kayo Hattori, Yujiro Nonaka, Hiroi Kasai, Shinobu Shimizu
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865419300687